A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 19 Oct 2019 This trial has been completed in spain, according to European Clinical Trials Database.
- 11 Oct 2019 Planned End Date changed from 6 Sep 2019 to 15 Nov 2019.
- 28 Aug 2019 Planned End Date changed from 15 Nov 2019 to 6 Sep 2019.